Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy

Adhesion molecules play a major role in chronic inflammatory conditions such as rheumatoid arthritis (RA). The rheumatoid synovitis is characterised by a mononuclear cell (MNC) infiltrate consisting of clusters of strongly HLA-DR positive antigen presenting cells in close contact with T lymphocytes,¹ the majority of which express the helper/memory phenotype (CD4 + CD45R0+).² These immunoreactive foci are thought to be the patho-genetic units responsible for the initiation and perpetuation of RA. This inflammatory infiltrate is generated by a series of events which include the migration of leucocytes from the blood stream into the tissues, their activation to effector cells and, finally, their retention locally to facilitate the ongoing immune reaction. Adhesion molecules are involved in all these phases: first, they mediate the interaction of leucocyte with vascular endothelial cells (EC) during the phenomenon of migration; second, they aid cell contact and deliver costimulatory signals during Ag presentation and cell activation and third, they allow leucocyte adhesion to extracellular matrix components for local retention.

The first step of leucocyte migration is represented by adhesion to vascular endothelium which has been shown to be a complex multistep process.³ In the first instance, leucocytes attach to the EC in the post-capillary venules by means of selectin molecules which bind to their oligosaccharide ligands. Following activation by cytokines released during inflammation, stronger bonds are formed using the β1 (VLA-4) and β2 (LFA-1 and MAC-1) integrins which bind to their Ig superfamily counter-receptors, VCAM-1 and ICAM-1 respectively.⁴ This more stable adhesion allows transendothelial migration resulting in cell extravasation into the inflamed tissues. The increased ability of CD45R0+ T lymphocytes to bind to EC in vitro and to migrate into epidermal suction blisters in vivo may explain the predominance of these cells at sites of chronic inflammation.⁵ ⁶ Adhesion molecules also play a major role in the second phase or homotypic/heterotypic cell clustering which is responsible for the formation of the characteristic perivascular MNC aggregates typical of the RA synovium. This process provides the necessary physical conditions for Ag presentation/response and other vital immune functions requiring cell contact. It is primarily dependent on two adhesion receptor/counter-receptor pairs: LFA-1/ICAM-1 and CD2/LFA3. In the third phase, adhesion molecules are critically important for the binding of inflammatory cells to extracellular matrix components (ECM) such as fibronectin (FN) and collagen (COL) via the β1 integrins (VLA6).⁷ Adhesion molecules do not merely act as intercellular anchors but, engaged by their natural ligands, either FN⁸ or purified VCAM-1 or ICAM-1⁹ transmit costimulatory signals capable of activating immune cells.

Following the process of activation, adhesion molecules are shed from the cell surface and can be measured in soluble form in the serum. These circulating adhesion molecules have been found to be increased in several autoimmune diseases including RA, SLE and vasculitis.¹⁰ Although in most cases there is little relation between soluble adhesion molecule levels and disease activity,¹⁰ in RA a correlation between circulating VCAM-1, but not ICAM-1, has been shown.¹¹ The relevance of these soluble forms in disease pathogenesis or the regulation of adhesion remains to be determined; it is possible, however, that these molecules can act as inhibitors of adhesion processes.¹² In this respect, it is also interesting that some acute phase proteins, such as the α1 acid glycoprotein (orosomucoid), may inhibit selectin mediated leucocyte endothelial interactions.¹²

The regulation of adhesion mechanisms therefore is likely to have an important therapeutic role in the treatment of RA. There has been a renewed interest in studying the effects of well known therapeutic agents on these processes; in addition, new modalities have been developed.

Effects of known therapeutic agents on adhesion related phenomena

Corticosteroids (CS) are known to induce neutrophilia with lymphopenia in the blood but produce a concomitant decrease of both leucocyte types in inflamed tissues such as the RA synovium.¹³ The mechanism by which this occurs is not completely clear, although interference with the phenomena of migration and recirculation seems an attractive possibility. Support for this idea comes from recent in vitro studies which demonstrate that CS are able to inhibit neutrophil (PMN) EC binding by inhibiting the expression of ELAM-1 and ICAM-1 molecules on EC.¹⁴ As far as lymphocytes are concerned, CS down regulate the expression of LFA-1 and CD2 following activation, with a consequent decrease in adhesion to endothelium.¹⁵
Colchicine and methotrexate (MTX) have been shown to decrease in vivo leucocyte adhesion and migration in rat mesenteric venules stimulated with platelet activating factor (PAF). This effect is related to the ability of MTX to increase adenosine release since adenosine inhibits the production of superoxide which is known to increase leucocyte-EC adhesion. Sulphasalazine, but not sulphapyridine (inactive moiety), has been shown to inhibit the activation-dependent upregulation of CD11b/CD18 (MAC-1) by granulocytes and monocytes but not lymphocytes. Gold treatment decreases the expression of ELAM-1 by synovial EC in patients with RA. Finally, in patients with psoriasis, cyclosporin A (CyA) has been shown to reduce dramatically the number of T cells infiltrating the skin and the expression of ICAM-1 on keratinocytes although, interestingly, not on EC.

New therapeutic modalities
The therapeutic potential of mAbs against adhesion molecules has been demonstrated in a variety of animal models including allograft rejection, cardiac reperfusion injury and experimental autoimmune encephalomyelitis. As far as arthritis is concerned, blocking either the LFA-1 or the VLA-4 pathways has been shown to inhibit disease in animals. As a result of these studies, a trial using anti ICAM-1 mAb has been conducted in RA. The patients showed a transient improvement which correlated with the development of a peripheral blood lymphocytosis suggesting that inhibition of lymphocye migration into inflammatory sites was occurring. However, the therapeutic effect could also have arisen by inhibiting other adhesion-dependent immune functions in which ICAM-1 plays a major role such as T cell activation. Several other ways of modulating cell adhesion are currently being investigated. Of great interest is the use of synthetic oligosaccharides to block the terminal sugars on selectin molecules and the use of soluble and recombinant ICAM-1 constructs.

Summary
The essential role played by cell adhesion and migration in the generation of chronic synovitis is now beyond doubt. Some of the beneficial effects of currently used drugs may be related to their ability to interfere with these mechanisms. The complexity of the process, however, means that there are many potential targets for therapeutic intervention and therefore further studies of the basic mechanisms are necessary to identify those which are most important.

Rheumatology Unit,
Guy's Hospital,
London SE1 9RT,
United Kingdom

Correspondence to: Dr Costantino Pitzalis, Rheumatology Unit, Division of Medicine, Guy's Hospital, St Thomas Street, London SE1 9RT, United Kingdom

3 Butcher E C. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. [Review]. Cell 1991; 67: 1035-6.
Adhesion molecules in rheumatoid arthritis: role in the pathogenesis and prospects for therapy.
C Pitzalis, G Kingsley and G Panayi

doi: 10.1136/ard.53.5.287

Updated information and services can be found at:
http://ard.bmj.com/content/53/5/287

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/